Reuters logo
1 个月内
BRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published
2017年6月26日 / 中午11点47分 / 1 个月内

BRIEF-Dermira says findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published

1 分钟阅读

June 26 (Reuters) - Dermira Inc

* Dermira - Findings from nonclinical studies evaluating mechanism of action for olumacostat glasaretil in sebum inhibition were published

* Dermira Inc - An additional open-label trial, claritude, is evaluating long-term safety of olumacostat glasaretil.

* Dermira Inc - Topline results from clareos-1 and clareos-2 trials are expected in first half of 2018. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below